ESPR Esperion Therapeutics Inc.

-0.94  -2%
Previous Close 50.51
Open 50.37
Price To book 7.27
Market Cap 1119943040
Shares 22,593,162
Volume 351,407
Short Ratio 5.29
Av. Daily Volume 702,513

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 initiation announced July 26, 2017 - data due 1Q 2018.
Bempedoic Acid - 1002-039
Phase 2 data released August 8, 2017. Primary endpoint met.
Bempedoic Acid/ Ezetimibe/ Atorvastatin (1002-038)
Phase 2 (PK/PD) top-line data met primary endpoint - October 2016.
Bempedoic acid (ETC-1002-035)
Patients treated with high-dose statin therapy
Phase 3 initiation of efficacy trials announced January 8, 2017. Data due 2Q and 3Q 2018.
Bempedoic acid - CLEAR LDL-C Lowering Program 1002-046, 1002-047 and 1002-048
Hypercholesterolemia - statin intolerance
Phase 3 long-term safety and tolerability trial initiated January 2016. Completion of enrollment announced January 25, 2017. Top-line results due 2Q 2018.
Bempedoic acid (ETC-1002-040) - Clear Harmony
Hyperlipidemia whose LDL-C is not adequately controlled with low- and moderate-dose statins
Phase 2 data released July 2015
Bempedoic acid ETC-1002-014
Hypercholesterolemia and hypertension

Latest News

  1. Cramer Remix: Here's how North Korea's missile could impa...
  2. Cramer Remix: Here's how North Korea's missile could impact the stock market
  3. These Stocks Have Quadrupled Since Last Year
  4. Edited Transcript of ESPR earnings conference call or presentation 8-Aug-17 12:30pm GMT
  5. The Zacks Analyst Blog Highlights: Mylan, Perrigo, Esperion's, Zynerba and Valeant
  6. Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  7. Pharma Stock Roundup: Mylan Misses, Perrigo Tops in Q2, Zynerba Plunges on Study Failure
  8. Esperion Prices Public Offering of Common Stock
  9. Today's Research Reports on Stocks to Watch: Esperion Therapeutics and Valeant Pharmaceuticals
  10. Esperion Therapeutics reports 2Q loss
  11. Esperion Announces Proposed Public Offering of Common Stock
  12. Here's What's Pushing Up Esperion Therapeutics Inc. Today
  13. Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Second Quarter 2017 Financial Results
  14. Esperion Announces Positive Top-Line Results From Phase 2 Study of Bempedoic Acid / Ezetimibe Combination Plus Atorvastatin
  15. Investor Network: Esperion Therapeutics, Inc. to Host Earnings Call
  16. Should You Buy Esperion Therapeutics (ESPR) Ahead of Earnings?
  17. Esperion to Provide Bempedoic Acid Franchise Development Program Updates and Second Quarter Financial Results
  18. What to Expect from Epizyme (EPZM) This Earnings Season?
  19. What's in the Cards for Endo (ENDP) this Earnings Season?
  20. Esperion Announces Initiation of Phase 2 Study of Bempedoic Acid Added-On to a PCSK9 Inhibitor

SEC Filings

  1. SC 13G - Statement of acquisition of beneficial ownership by individuals 171042824
  2. 8-K - Current report 171021511
  3. 424B5 - Prospectus [Rule 424(b)(5)] 171021448
  4. 424B5 - Prospectus [Rule 424(b)(5)] 171015338
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 171014647
  6. 8-K - Current report 171013318
  7. 8-K - Current report 171013317
  8. 8-K - Current report 17986692
  9. 8-K - Current report 17930176
  10. S-8 - Securities to be offered to employees in employee benefit plans 17855263